CDCP1: A promising diagnostic biomarker and therapeutic target for human cancer

Xiao Qi; Jing Gao; Zihao Li; Guangxin Zhang; Jialin Li; Yilin Fu; Mingjun Cai; Hongda Wang; Ti Tong

doi:10.1016/j.lfs.2022.120600

CDCP1: A promising diagnostic biomarker and therapeutic target for human cancer

Life Sci. 2022 Jul 15:301:120600. doi: 10.1016/j.lfs.2022.120600. Epub 2022 May 2.

Authors

Xiao Qi¹, Jing Gao², Zihao Li³, Guangxin Zhang⁴, Jialin Li⁵, Yilin Fu⁶, Mingjun Cai⁷, Hongda Wang⁸, Ti Tong⁹

Affiliations

¹ Department of thoracic surgery, The Second Hospital of Jilin University, Changchun, Jilin 130041, China. Electronic address: qixiao20@mails.jlu.edu.cn.
² State Key Laboratory of Electroanalytical Chemistry, Research Center of Biomembranomics, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin 130022, China. Electronic address: gaojing@ciac.ac.cn.
³ Department of thoracic surgery, The Second Hospital of Jilin University, Changchun, Jilin 130041, China. Electronic address: zhl19@mails.jlu.edu.cn.
⁴ Department of thoracic surgery, The Second Hospital of Jilin University, Changchun, Jilin 130041, China. Electronic address: guangxinzhang@jlu.edu.cn.
⁵ Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130012, China.
⁶ Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China. Electronic address: fuyl18@mails.jlu.edu.cn.
⁷ State Key Laboratory of Electroanalytical Chemistry, Research Center of Biomembranomics, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin 130022, China. Electronic address: caimingjun@ciac.ac.cn.
⁸ State Key Laboratory of Electroanalytical Chemistry, Research Center of Biomembranomics, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin 130022, China; University of Science and Technology of China, Hefei, Anhui 230027, China; Laboratory for Marine Biology and Biotechnology, Qing dao National Laboratory for Marine Science and Technology, Wenhai Road, Aoshanwei, Jimo, Qingdao, Shandong 266237, China. Electronic address: hdwang@ciac.ac.cn.
⁹ Department of thoracic surgery, The Second Hospital of Jilin University, Changchun, Jilin 130041, China. Electronic address: tongti@jlu.edu.cn.

PMID: 35504333
DOI: 10.1016/j.lfs.2022.120600

Abstract

CUB domain-containing protein 1 (CDCP1), as an emerging transmembrane protein, is overexpressed in a variety of malignant tumors including respiratory tumors, digestive system cancers, hematological malignancies and urogenital cancers. Several cancer-related proteins have been reported to interact with CDCP1. It acts as a crucial hub in multiple classical signaling pathways of tumorigenesis and progression. Its overexpression and activation are also associated with prognosis and drug resistance. Due to its important roles in malignant tumors, CDCP1 is expected to be a promising therapeutic target for treatment and a new biomarker for diagnosis. In this article, we review the roles of CDCP1 in diagnosis and management of malignant tumors, and also its regulation in several essential tumor-related pathways.

Keywords: Biomarker; CUB domain-containing protein 1; Cancers; Metastases; Targeted therapy; Tumorigenesis.

Publication types

Review

MeSH terms

Antigens, Neoplasm* / metabolism
Cell Adhesion Molecules
Cell Line, Tumor
Humans
Neoplasms* / diagnosis
Neoplasms* / drug therapy
Signal Transduction

Substances

Antigens, Neoplasm
CDCP1 protein, human
Cell Adhesion Molecules